Skip to content
Open access

Electrophysiological dependent antiarrhythmic drug response in population-based models of paroxysmal atrial fibrillation

Sep 2026 · bioRxiv · 0 citations · 67 references
Biology

Abstract

Response to antiarrhythmic drugs varies markedly across patients with atrial fibrillation (AF), suggesting that treatment efficacy depends on the interaction between drug-specific mechanisms and patient-specific electrophysiological substrate. Here, we used population-based computational models to investigate how electrophysiological substrate and inter-individual ionic variability influence pharmacological efficacy and the underlying mechanisms. Two populations of human atrial models were generated from distinct substrates: a reference left atrial model and a second model incorporating inward-rectifier-enhancement (IRE) through a 2-fold increase in IK1 and IK,ACh. Both populations were independently calibrated against the same experimental datasets from patients with paroxysmal AF (pAF), yielding pAF and IRE-pAF populations. Sustained reentrant activity was induced in two-dimensional tissue simulations and subsequently used to assess cardioversion efficacy of flecainide, vernakalant and tertiapin-Q. Despite satisfying the same calibration criteria, IRE-pAF population exhibited a more arrhythmogenic phenotype: shorter refractoriness, higher dominant frequency (DF) and greater rotor stability. Antiarrhythmic efficacy markedly differed between substrates. Flecainide cardioversion decreased in IRE-pAF compared with pAF (34% vs 21%), whereas IK,ACh-targeting therapies preserved or improved efficacy in IRE-pAF (vernakalant: 41% vs 44%, tertiapin-Q: 11% vs 18%). Across drugs and substrates, rotor DF strongly influenced cardioversion outcome, with higher-frequency rotors showing lower termination rates. Drug-induced DF reduction emerged as a key mechanism associated with successful cardioversion, whereas effective refractory period (ERP) prolongation alone did not consistently explain treatment efficacy. In pAF, vernakalant achieved higher cardioversion efficacy than flecainide despite a smaller increase in ERP and greater DF reduction. Ionic analyses further showed that elevated IK,ACh favored responses to vernakalant and tertiapin-Q. These findings demonstrate that cardioversion efficacy emerges from the interaction between electrophysiological substrate, rotor dynamics and drug-specific mechanisms. In particular, substrates differing in inward rectifier activity exhibit distinct response patterns, while DF emerges as a robust marker of pharmacological susceptibility and a potential guide for drug-mediated AF termination. Author summary Antiarrhythmic drugs are commonly used to restore normal rhythm in patients with paroxysmal atrial fibrillation (pAF), but their effectiveness varies substantially among individuals. The reasons underlying this variability remain incompletely understood, limiting our ability to select the most appropriate treatment for a given patient. In this study, we used populations of computational models of human atrial tissue to investigate how differences in the underlying electrophysiological substrate influence drug response and the underlying mechanisms. We generated two pAF-like populations differing in the level of inward rectifier activity. Then, we evaluated the effects of three antiarrhythmic drugs with distinct mechanisms of action. Our results show that, while some therapies became less effective in the inward-rectifier-enhanced substrate, others maintained or even improved their performance. We also found that rotor dominant frequency (DF) was closely linked to treatment success and that drugs producing greater DF reduction were more likely to terminate AF. These findings highlight the importance of considering substrate-specific electrophysiology when evaluating antiarrhythmic therapies and illustrate how computational modeling can help uncover mechanisms of drug response. More broadly, our results suggest that electrophysiological markers such as DF may help identify patients more likely to benefit from specific rhythm-control strategies, supporting future personalized approaches for AF treatment.

Read PDF

Similar papers

Open access Oct 2026

Human atrium-scaled in vitro modelling of atrial fibrillation: size-dependent arrhythmia dynamics and pharmacological responses

Atrial size strongly influences atrial fibrillation (AF) development, maintenance, and therapeutic outcome, including pharmacological cardioversion. Yet, preclinical research relies heavily on models considerably smaller than the human atrium, thereby not supporting the spacious arrhythmia dynamics seen in human...

A. Nobacht, T. De Coster, S. Deng et al. · 0 citations
Open access Oct 2026

Extra-pulmonary vein drivers as a potential mechanism of the antiarrhythmic drug-resistant atrial fibrillation after catheter ablation: Digital twin-guided virtual drug test

Findings suggest that persistent extra-PV PS drivers may contribute to AAD-resistant AA recurrence after PVI, and limited suppression of stable PS area under Virtual AADs, but not restitution response, predicts 3-year Clinical AA recurrence.

T. Hwang, D. Ahn, K. Im et al. · 0 citations
Open access Oct 2026

Non-sustained atrial tachyarrhythmia episodes as predictors of atrial fibrillation: should they be ignored?

Non-sustained atrial tachyarrhythmias (ATAs) lasting less than 30 seconds have traditionally been considered clinically insignificant. However, recent evidence suggests that even these brief episodes may serve as markers of electrophysiological instability and predictors of progression to atrial fibrillation (AF)...

T. Danilevich, L. Rasputina · 0 citations
Open access Sep 2026

Comparative Analysis of Atrial Electrophysiology Across Animal Species and Humans: Enhancing Translation in Atrial Arrhythmia Research.

This study provides a reference for species-specific atrial action potential characteristics, linking functional properties to transcriptomic ion channel expression, and demonstrates that relative changes in action potential parameters can be inferred from transcriptomic data using in silico simulations.

A. Paasche, F. Wiedmann, C. Goetz et al. · 0 citations
Open access Nov 2026

Role of reverse remodelling in recurrence of atrial fibrillation after patient-tailored catheter ablation.

BACKGROUND AND AIMS Catheter ablation (CA) is a curative treatment for atrial fibrillation (AF), yet success rates remain sub-optimal, with ∼50% of patients with persistent AF experiencing recurrence after 1 year. This may be due to the self-perpetuating nature of AF, which remodels atrial structure and cellular proper...

G. Obada, S. Ogbomo-Harmitt, M. Deprez et al. · 0 citations
Open access Oct 2026

Dynamics of P wave Morphological Variability Preceding the Onset of Atrial Fibrillation.

Although the problem of predicting atrial fibrillation (AF) has been extensively studied, the electrophysiological changes that precede AF onset remain insufficiently understood. From a clinical perspective, better understanding of such changes should facilitate future monitoring, prediction strategies, and therapeutic...

M. Noriega, A. Martín-Yebra, M. Stridh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.